

Special Issue

Personalized Medicine in Metabolic Syndrome—Challenges and Opportunities

Message from the Guest Editor

In this Special Issue, original research articles and reviews are welcome. Research areas may include (but are not limited to) the following:

- Metabolic syndrome and cancer;
- Prevalence and risk factors for diabetes and obesity in children: Cross sectional study;
- The Effects of Ramadan Fasting on Children and Young Adults with Type 2 Diabetes during COVID-19 Pandemic in the UK: Prospective Study;
- Intermittent fasting and non-alcoholic fatty liver;
- Hyperbaric oxygen as treatment for diabetic foot;
- Role of pharmacist in the management of diabetes;
- Unveiling the Promise of Personalized Medicine for Diabetes, Obesity, and Metabolic Syndrome: A Comprehensive Review;
- From One-Size-Fits-All to Tailored Approaches: A Systematic Review of Personalized Medicine Strategies in Diabetes;
- Bariatric surgery;
- Thiamine deficiency in diabetes, obesity, and bariatric surgery: Recipes for diabetic ketoacidosis;
- Diverticulosis and diabetes;
- Interventional studies by pharmacists in the management of diabetes.

Guest Editor

Dr. Mohamed H. Ahmed

1. Department of Geriatric Medicine, Milton Keynes University Hospital NHS Foundation Trust, Eaglestone, Milton Keynes, UK

2. Department of Medicine and HIV Metabolic Clinic, Milton Keynes University Hospital NHS Foundation Trust, Eaglestone, Milton Keynes, UK

Deadline for manuscript submissions

25 June 2025



Journal of Personalized Medicine

an Open Access Journal
by MDPI

Impact Factor 3.0
CiteScore 4.1
Indexed in PubMed




mdpi.com/si/185129

*Journal of Personalized
Medicine*
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
jpm@mdpi.com

mdpi.com/journal/

[jpm](https://jpm.mdpi.com)





Journal of Personalized Medicine

an Open Access Journal
by MDPI

Impact Factor 3.0
CiteScore 4.1
Indexed in PubMed



mdpi.com/journal/

jpm



About the Journal

Message from the Editor-in-Chief

Journal of Personalized Medicine (JPM), ISSN 2075-4426) is an international, open access journal aimed at bringing all aspects of personalized medicine to one platform. *JPM* publishes cutting edge, innovative preclinical and translational scientific research and technologies related to personalized medicine (e.g., precision medicine, pharmacogenomics/proteomics, systems biology, 'omics association analysis). *JPM* is covered in Scopus, the Science Citation Index Expanded (SCIE), PubMed, PMC, Embase, and other databases.

Editor-in-Chief

Prof. Dr. David Alan Rizzieri

1. Novant Health Cancer Institute, Winston-Salem, NC 27103, USA

2. Division of Hematologic Malignancies and Cellular Therapy, Duke University, Durham, NC 27710, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, and other databases.

Journal Rank:

JCR - Q1 (Medicine, General and Internal) / CiteScore - Q2 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 16.7 days after submission; acceptance to publication is undertaken in 2.5 days (median values for papers published in this journal in the first half of 2024).